AstraZeneca strikes $40 million AI drug discovery deal with insitro

AstraZeneca and insitro Launch $40 Million AI-Driven Drug Discovery Deal

AI Collaboration Targets Liver and Heart Diseases

By Patrick Wingrove

Overview of the Partnership

LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro to discover and develop new treatments for difficult to treat liver and heart conditions, the British drugmaker said on Thursday.

Financial Terms and Potential Milestones

Under the agreement, AstraZeneca will pay $40 million up front, with California-based insitro eligible for up to about $1.46 billion in potential development and commercial milestones, as well as a single-digit percentage of future sales in royalties.

Focus Areas and Technology

Targeted Diseases: MASH and Cardiomyopathies

The multi-year collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, a group of diseases that affect the heart muscle. Both have historically lacked effective therapies because researchers have struggled to pinpoint their root biological drivers, the drugmaker said.

AI Platform: Virtual Human

Insitro will use its "Virtual Human" AI platform, which combines lab-grown cell models and machine learning, to identify causal disease biology and advance AstraZeneca-nominated targets from discovery to development-candidate stage. AstraZeneca will then run and fund future clinical trials.

Insitro’s Growing Industry Presence

Recent Partnerships

Bristol Myers Squibb Collaboration

The deal builds on insitro's expansion across the pharmaceuticals industry. The biotech company recently expanded its partnership with Bristol Myers Squibb to advance a broader portfolio of targets for amyotrophic lateral sclerosis (ALS).

Eli Lilly AI Model Initiative

It also teamed up with Eli Lilly to build AI models that predict pharmacological properties of small molecules in living organisms.

Expert Insights

Challenges in Drug Discovery

"Choosing the new targets that we want to put into our discovery pipeline is one of the hardest things we do across research and development," Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, told Reuters.

"By the time we read about a new pathway or target (in major scientific journals), it is no longer novel. It's in the public domain and we're already a few steps too late. But when we identify these unique connections early and test them in cellular systems, we're ahead of the game."

AI and Scientific Expertise

Barr added that pairing AI tools with experienced scientists allows the company to test fewer molecules in the lab, reduce guesswork and speed the search for effective medicines.

(Reporting by Patrick Wingrove in LondonEditing by David Goodman)